GlassScriptPhysician profile
Walter C Pearcy
NPI 1003873530
$2,993.77
in general payments reported to CMS, 2019-2025
22 companies · $24.48 in 2025
The $24.48 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $404 · 2021: $486 · 2022: $758 · 2023: $310 · 2024: $59.06 · 2025: $24.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $669.92 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $389.70 | 2019-2023 | |
| Amgen INC. | $347.83 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $274.99 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $269.42 | 2019-2023 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.11 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $214.02 | 2021-2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $156.96 | 2019-2023 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $79.75 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $71.86 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $36.68 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $31.95 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.11 | 2019-2021 | |
| Edwards Lifesciences Corporation | $28.19 | 2019 | |
| Cordis US Corp. | $24.48 | 2025 | Mynx Control |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $23.03 | 2022 | |
| Atricure, INC. | $19.42 | 2022 | |
| Abbott Laboratories | $17.89 | 2022 | |
| Quidel Corporation | $16.69 | 2019 | |
| Lundbeck LLC | $16.46 | 2020 | |
| Medtronic, INC. | $15.82 | 2023 | Arctic Front Advance |
| Novo Nordisk INC | $13.49 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Pearcy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.